
Oncology NEWS International
- Oncology NEWS International Vol 15 No 6
- Volume 15
- Issue 6
Phase I Trial of NPI-0052 Begins
Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
SAN DIEGO, CalifNereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.
Articles in this issue
over 19 years ago
Triple-Negative Cancers More Common in Young Black Ptsover 19 years ago
Artists Turn Flowers & Curves Into 'Forms' and 'Figures'over 19 years ago
Study to Examine Outcomes Disparities in Pediatric ALLover 19 years ago
Thalidomide Has 'Changed the Paradigm' in Myeloma Rxover 19 years ago
CA4P Gets Orphan Drug Statusover 19 years ago
Testicular Ca Survivors at Increased Risk for CV Eventsover 19 years ago
A Novel Brings a Cancer Research Laboratory to Lifeover 19 years ago
NCCN Reveals New Venous Thromboembolism Guidelineover 19 years ago
Lapatinib New Option for Metastatic HER2+ Breast Caover 19 years ago
FDA Approves Dacogen for Treating All MDS SubtypesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































